• No results found

INNOVATION IN CNS DRUG DISCOVERY: FROM SMALL MOLECULES TO BIOLOGIC THERAPIES

N/A
N/A
Protected

Academic year: 2021

Share "INNOVATION IN CNS DRUG DISCOVERY: FROM SMALL MOLECULES TO BIOLOGIC THERAPIES"

Copied!
9
0
0

Full text

(1)

INTERNATIONAL PhD PROGRAM IN NEUROPHARMACOLOGY UNIVERSITY OF CATANIA

SUMMER SCHOOL OF NEUROSCIENCE (11)

Undicesima Scuola Estiva di Neuroscienze (11)

UNDER THE AUSPICES

OF THE FEDERATION OF EUROPEAN PHARMACOLOGICAL SOCIETIES (EPHAR)

THE ITALIAN SOCIETY OF PHARMACOLOGY (SIF)

AND THE ITALIAN SOCIETY OF NEUROPSYCHOPHARMACOLOGY (SINPF)

July 6-12, 2013

INNOVATION IN CNS DRUG DISCOVERY:

FROM SMALL MOLECULES TO BIOLOGIC THERAPIES

Catania

Aula Magna

Palazzo Centrale dell’Università

Piazza Università, 2

(2)

Chairman

Filippo Drago

(Catania)

Scientific Secretariat

Filippo Caraci

(Catania)

Scientific Committee

Eugenio Aguglia

(Catania)

Claudio Bucolo

(Catania)

Pier Luigi Canonico (Novara)

Donatella Marazziti

(Pisa)

Giancarlo Pepeu (Florence)

Giorgio Racagni (

Milan)

Salvatore Salomone (Catania)

(3)

Saturday July 6

th

, 2013

09.00-09.45 Registration 09.45-10.00 Opening remarks

Filippo Drago (Catania)

10.00-11.00 Opening lecture (introduced by Filippo Drago)

Innovation in neuroscience: which implications for CNS drug research ?

Siegfried Kasper (Austria)

11.00-11.30 Welcome reception

Innovation in CNS drug discovery: general principles

Introduced and moderated by Mariano Malaguarnera (Italy)

16.00-17.00 Role of neuroimaging in CNS drug discovery

Richard G. Wise (United Kingdom)

17.00-18.00 Genomics and pharmacogenomics of brain disorders: implications for CNS drug research

Ramon Cacabelos (Spain)

18.00-18.30 Discussion

18.30-19.30 Clinical trials design for disease-modifying drugs: the role of biological markers

Daniela Galimberti (Italy)

(4)

Sunday July 7

th

, 2013

CNS disorders in childhood: new targets and new drugs

Introduced and moderated by Salvatore Salomone (Italy)

10.00-11.00 Pathways to drug development for autism spectrum disorders

Kathryn Chadman (USA)

11.00-12.00 New pharmacological approaches to neurocutaneuos disorders

Martino Ruggieri (Italy)

12.00-12.15 Discussion

12.15-1315 Sponsored lecture by Biogen Idec

New Perspectives for MS Treatment: focus on BG-12 mechanism of action

Ralf Gold (Germany)

Multiple sclerosis

Introduced and moderated by Giorgio Racagni (Italy)

16.00-17.00 Immunomodulatory treatment strategies in multiple sclerosis

Ferdinando Nicoletti (Italy)

17.00-1800 Neuroprotection and repair in multiple sclerosis

Rina Aharoni (Israel)

18.00-18.30 Discussion 18.30-19.30 Special Lecture:

Novel drugs for the treatment of multiple sclerosis: from biologic to small molecules ?

Giancarlo Comi (Italy)

(5)

Monday July 8

th

, 2013

Schizophrenia

Introduced and moderated by Eugenio Aguglia (Italy)

10.00-11.00 Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

Neil Dawson (United Kingdom)

11.00-12.00 Novel antipsychotic drugs for schizophrenia

Edoardo Spina (Messina)

12.00-12.30 Discussion

12.30-13.00 Sponsored lecture by Zambon Group

Glutamate-dopamine interaction in the pathogenesis of Parkinson’s disease: new targets for the treatment

Paolo Barone (Italy)

Depression

Introduced and moderated by Donatella Marazziti (Italy)

16.00-17.00 Antistress properties of antidepressant drugs and their clinical implications

Marco Riva (Italy)

17.00-18.00 The cytokine hypothesis of depression: new targets for adjunctive treatments in depression

Nicoletta Brunello (Italy) 12.00-12.31 Discussion

18.30-19.31 Special Lecture:

Emerging therapies for depression

Ronald Duman (USA)

(6)

Tuesday July 9

th

, 2013

Neurodegenerative disorders

Introduced and moderated by Maria Angela Sortino (Italy)

10.00-11.00 The kynurenine pathway in neurodegenerative disorders

Francesca M. Notarangelo (USA)

11.00-12.00 Cell therapies for ischemic stroke - are we ready for clinical translations ? Johannes Boltze (Germany)

12.00-1300 Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

Francesco Fornai (Italy)

13.00-13,30 Discussion

Alzheimer’s disease

Introduced and moderated by Giancarlo Pepeu (Italy)

16.00-17.00 Target identification for drug discovery in AD

Monica Di Luca (Italy)

17.00-18.00 Neuroinflammation in AD: perspectives for drug development

Claudio Cuello (Canada)

18.00-18.30 Discussion

18.30-19.30 Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Cynthia A. Lemere (USA)

(7)

Wednesday July 10

th

, 2013

Drug discovery in ocular pharmacology

Introduced and moderated by Claudio Bucolo(Italy)

10.00-11.00 Retinal neuroprotection: novel pharmacological targets

Rossella Russo (Italy)

11.00-12.00 Neuroprotection in glaucoma

M. Francesca Cordeiro (United Kingdom)

12.00-12.30 Discussion

Parkinson’s disease

Introduced and moderated by Pier Luigi Canonico (Italy)

16.00-17.00 Drug discovery in PD: evidence from animal models

David T. Dexter (United Kingdom)

17.00-18.00 Pharmacological treatment of Parkinson’s disease: current options and new avenues

Mario Zappia (Italy) 18.00-18.30 Discussion

18.30-19.30 Neuroprotection in PD

Miquel Vila (Spain)

(8)

Thursday July 11

th

, 2013

Epilepsy

Introduced and moderated by Carmela Parenti (Italy)

10.00-11.00 New horizons in the development of antiepileptic drugs: the search for new targets

Anna Maria Vezzani (Italy)

11.00-12.00 Novel drugs for epilepsy

Emilio Perucca (Italy)

12.00-12.30 Discussion

Chronic Pain Syndromes

Introduced and moderated by Fabio Tascedda (Italy)

16.00-17.00 New strategies for target identification in chronic pain

Santina Chiechio (Italy)

17.00-18.00 Peripheral mechanisms of pain and analgesia: implications for drug development

Cristophe Stein (Germany)

18.00-18.30 Discussion

18.30-19.30 Neuropathic pain: diagnosis, pathophysiological mechanisms and treatment

Ralf Baron (Germany)

(9)

Friday July 12

th

, 2013

Innovation in CNS drug discovery: from small molecules to biologic therapies

Introduced and moderated by Filippo Caraci (Italy)

10.00-11.00 Can we vaccinate against affective disorders ?

Stefan Reber (Germany)

11.00-12.00 Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair

Hari Shankar Sharma (Sweden)

12.00-12.15 Discussion

12.15-13.15 Sponsored lecture by Roche

Glutamatergic system as a new target for the treatment of negative symptoms in schizophrenia

Ferdinando Nicoletti (Italy)

13.15-13.30 Closing remarks

Filippo Drago (Catania)

References

Related documents

Evaluating core principles of PRME against a framework based on Sen’s capabilities such as human well-being, pluralism and social participation, the conclusion is that PRME and its

JAL Mileage Bank (JMB) Members can earn bonus miles for an eligible rate plan (J-SMART) when staying at Nikko Hotels International and Hotel JAL City hotels...

repeat text at notated pitch but random rhythm- each singer vary pace - (effect of emotional crowd all talking at

N/A  NOT  Satisfied  8:00 AM  9:00 AM  186  149  10:00 AM  11:00 AM  50  42  11:00 AM  12:00 PM  73  76  12:00 PM  1:00 PM  134  99  2:00 PM  3:00 PM  75  59 

Featuring open edge computing platforms, the IG502 is capable of data optimization, real-time response, agile connection and intelligent analysis on the IoT edge, thus

Never exits the module Resides in volatile memory in plaintext Data encryption/decryp tion for IPSec sessions IPSec Preshared Session Key Triple-DES, AES- 128, AES-256

daily press review, daily news summary, daily news digest, media alerts, thematic media review, weekly previews and daily social media summaries deliverable on working days

5:00 AM 5:30 AM 6:00 AM 6:30 AM 7:00 AM 7:30 AM 8:00 AM 8:30 AM 9:00 AM 9:30 AM 10:00 AM 10:30 AM 11:00 AM 11:30 AM 12:00 PM 12:30 PM 1:00 PM 1:30 PM 2:00 PM 2:30 PM 3:00 PM 3:30

Keywords: Electronic health record, User interface design, Data visualization, Physician workflow, Knowledge manage- ment, Usability, Medical chart.. Abstract: An Electronic

Mathematics/Computer Science: 6-8 credits Any MAT General Education course Any CIS General Education course Wellness & Exercise Sci.: 3 credits WEX 101 and WEX-DHF-EXP

Cybersecurity is a key area of risk management for businesses and organizations, and has been demonstrated to affect information systems early in the life cycle

Further, on- peak spot market power prices are just a little lower than prices that can be bought in on a forward basis.. Note the prompt and 12 month strip on the figure above –

This equation expresses the total delay as a linear function of the primary delay, given the number of trains and stations, the timetable allowance and the buffer time.. The

● SIB (scale, index, base) byte ── when the addressing-mode specifier indicates that an index register will be used to compute the address of an operand, an SIB byte

• neural network architecture contained 11 input signals (sale, production, consumption and losses of water, num- ber of water-meters, length and number of failures of water

In a share transfer, all the company’s obligations and liabilities remain in the company whereas in a business sale, subject to the Transfer of Businesses (Protection of

Through the experimental results, we validated that the IIFDL improved root-mean-square error (RMSE) by 29.98% and prediction overshoot by 70.93%, compared with existing methods.

The aims of this project is to develop a smart charging controller to enable controlled charging of electrical vehicles without overloading the grid (G2V), reduce the

Setting up your first basic store: This chapter covers creating a first basic store with Shopify and introduces the admin, where you’ll develop and run your store8. The key

Therefore, the present study attempts to fill the gap and explore this kind of phenomenon in Senior High School level, especially in Indonesian setting, where English

Hence, this article intends to examine the elements involved in care work, body work, and cross-border migration as they cohere in the embodied practices of migrant nurses trained

The main finding from this study was that the majority of adolescents exposed to bullying during lower secondary school do not continue to be exposed during upper secondary